We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Abnormal Prenatal Blood Test Results Could Indicate Hidden Maternal Cancers

By LabMedica International staff writers
Posted on 05 Dec 2024

Researchers have discovered previously undiagnosed cancers in 48. More...

6% of pregnant individuals who received abnormal results from prenatal cell-free DNA (cfDNA) testing, which is typically used to screen for chromosomal disorders in the fetus. The types of cancers found included colorectal, breast, lung, and pancreatic cancers, as well as lymphoma, cholangiocarcinoma, and renal carcinoma. The cfDNA screening test analyzes placental DNA fragments circulating in the maternal bloodstream to identify an extra chromosome or determine the baby’s sex. In addition to detecting fetal DNA, cfDNA testing also identifies DNA released from the mother’s red blood stem cells, and occasionally, it can reveal abnormal DNA that may indicate an undiagnosed cancer in an asymptomatic pregnant individual. This study was published in the New England Journal of Medicine.

The ongoing IDENTIFY study by the National Institutes of Health (NIH, Bethesda, MD, USA) is investigating the implications of abnormal cfDNA test results that may suggest the presence of cancer. For the current analysis, the researchers screened 107 participants from the IDENTIFY study for cancer using whole-body magnetic resonance imaging (MRI), standard medical diagnostic tests, and cfDNA sequencing. Out of these participants, 52 were diagnosed with cancer. The researchers found that whole-body MRI was the most effective method for detecting cancer in this group.

Traditional diagnostic methods, such as reviewing medical history, assessing symptoms, and performing physical examinations, proved limited in detecting cancer or pinpointing its location. Other abnormal cfDNA results were found to be related to fibroids (benign tumors of the uterus), discrepancies between placental and fetal chromosomes, and clonal hematopoiesis in the mother (a precursor to blood cancers). The researchers emphasized the need for further studies to confirm the cfDNA sequencing patterns identified in this study, which could help detect cancer in pregnant individuals with no obvious clinical symptoms.


Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
HPV Molecular Test
BD Onclarity HPV Assay
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.